You searched for "gene therapy"

193 results found

Things I’d tell my medical school self, had I known my first year on the job would be during a global pandemic

In a conversation with his younger self, a foundation doctor reflects on the contrast between his expectations of medicine at university and the reality of working during the coronavirus pandemic. Every doctor arrives at medical school with nervous anticipation, yet...

An eye on novel anti-cancer agents: an evidence-based approach to external eye assessment

Novel anti-cancer therapies have led to significant advancement in cancer treatment, however, they can be associated with external eye complications. It is important to be mindful of such adverse effects during assessment of patients enrolled in clinical trials. Annually, approximately...

Africa makes strides in tackling blinding eye diseases: highlights of annual conference

Introduction The 9th Annual Scientific Conference of the College of Ophthalmology of Eastern, Central and Southern Africa (COECSA) was held at the Bingu International Convention Centre in Lilongwe, Malawi in September 2022. The meeting was hosted by the Ophthalmological Society...

Sensitive cilia – eyelashes in health and disease

In health our eyelashes protect the eyes, but in disease they can disfigure, impair quality of life and threaten vision. In this review the authors discuss aspects of lashes that are relevant to all professionals working near the eyes and...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...

A case of ‘60-day glaucoma’

Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...

Discussing treatment modalities for bilateral wet AMD

A 65-year-old lady with bilateral wet AMD and vision of 6/24 comes with an internet search about current therapies. How do you explain the various treatment modalities available? There are two NICE approved treatments for wet age-related macular degeneration (AMD)....

A pituitary tumour from 1927

The author shares a clinical case from Edinburgh Royal Infirmary’s archives. It is not often in the course of a clinical career that one gets the opportunity to review a patient who had been treated by a pioneer neurosurgeon some...

Robotic assisted orbital surgery (RAOS) – a novel approach to orbital malignancy surgery

Robotic technology in ENT surgery has been used in certain areas of head and neck cancer care but, in this article, we hear of an exciting development from the team at Guy’s & St Thomas’. Advances in surgical robotic technology...

Identifying life-threatening uveal melanoma: A directed application of general-purpose AI

Uveal melanoma (UM) is a rare but aggressive eye cancer, affecting approximately six people per million annually [1]. Uveal melanoma arises in three locations: the choroid, ciliary body, and iris. As the most common primary intraocular malignancy in adults, UM...

A three-way partnership between Nigeria, Tanzania and Northern Ireland

VISION 2020 LINKS between Western Health and Social Care Trust (WHSCT), Altnagelvin Area Hospital, Northern Ireland with first ECWA Eye Hospital, Kano, Nigeria and now also with Mbeya Referral Hospital (MRH), Tanzania, have been beneficial to all three partners. From...

The Makassar-Dundee VISION 2020 LINK: a tale of two cities and two trainees

A resident’s view from Makassar My name is Hendra Kusuma, a final year resident (registrar) in the ophthalmology department at Hasanuddin University in Makassar, Indonesia. We have had a VISION 2020 LINK with Dundee (coordinated at the UK end by...